Deterioration of Glycemic Control during Octreotide LAR Treatment in an Acromegalic Japanese Patient with Type 2 Diabetes Mellitus
We report a case showing deterioration of glycemic control during octreotide long-acting release (LAR) treatment in an acromegalic Japanese patient with type 2 diabetes mellitus. The patient did not show much improvement of insulin sensitivity (QUICKI; 0.33 before treatment, 0.35 during octreotide L...
Gespeichert in:
| Veröffentlicht in: | Endocrine Journal 2007, Vol.54(2), pp.329-333 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 333 |
|---|---|
| container_issue | 2 |
| container_start_page | 329 |
| container_title | Endocrine Journal |
| container_volume | 54 |
| creator | KAHARA, Toshio UENO, Keiko TORITA, Muneyoshi USUDA, Rika ABE, Takumi |
| description | We report a case showing deterioration of glycemic control during octreotide long-acting release (LAR) treatment in an acromegalic Japanese patient with type 2 diabetes mellitus. The patient did not show much improvement of insulin sensitivity (QUICKI; 0.33 before treatment, 0.35 during octreotide LAR treatment), and showed a significant reduction in early insulin secretion (insulinogenic index; 0.28 before treatment, 0.08 during octreotide LAR treatment) on 75 g oral glucose tolerance test (75gOGTT), despite decreases in GH and IGF-I levels during the course of octreotide LAR treatment. Postoperatively, both insulin sensitivity and early insulin secretion on 75gOGTT were improved (QUICKI 0.59, insulinogenic index 0.35). There are some reports that insulinogenic index is lower in most Japanese patients with type 2 diabetes mellitus and that early insulin secretions are significantly suppressed after administration of octreotide LAR. Although the influence of octreotide LAR on glucose metabolism varies among individuals, it is necessary to manage the deterioration of glucose tolerance during octreotide LAR treatment in acromegalic Japanese patients with decreased insulinogenic index. |
| doi_str_mv | 10.1507/endocrj.K06-143 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1507_endocrj_K06_143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17339747</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-90cbfd210e91272fda04df61474cac2792273c6b7eac950654381efa1495b4773</originalsourceid><addsrcrecordid>eNpFkMtOAjEUhhujEUTX7kxfYKS3mU6XBO9iMAbXk07nDJTMhbQlhq1PbgkENz2Lfv9_2g-hW0ruaUrkGLqqN259_06yhAp-hoaUizwRqSDnaEgUzZNcpWqArrxfE8J5KvglGlDJuZJCDtHvAwRwtnc62L7DfY2fm52B1ho87bvg-gZXW2e7JZ6b4KAPtgI8m3zhhQMdWugCth3WHZ4Y17ew1E1MvumN7sAD_oyte-THhhVe7DaAGX6wuow7Pf6AprFh66_RRa0bDzfHOULfT4-L6Usymz-_TiezxIg8C4kipqwrRgkoyiSrK01EVWdUSGG0YVIxJrnJSgnaqJRk8ac5hVpTodJSSMlHaHzojS_13kFdbJxttdsVlBR7m8XRZhFtFtFmTNwdEptt2UL1zx_1RWB6ANY-6CWcAO2CNQ2cClNRsMPBmTrdmpV2EeF_jVCMSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Deterioration of Glycemic Control during Octreotide LAR Treatment in an Acromegalic Japanese Patient with Type 2 Diabetes Mellitus</title><source>MEDLINE</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>KAHARA, Toshio ; UENO, Keiko ; TORITA, Muneyoshi ; USUDA, Rika ; ABE, Takumi</creator><creatorcontrib>KAHARA, Toshio ; UENO, Keiko ; TORITA, Muneyoshi ; USUDA, Rika ; ABE, Takumi</creatorcontrib><description>We report a case showing deterioration of glycemic control during octreotide long-acting release (LAR) treatment in an acromegalic Japanese patient with type 2 diabetes mellitus. The patient did not show much improvement of insulin sensitivity (QUICKI; 0.33 before treatment, 0.35 during octreotide LAR treatment), and showed a significant reduction in early insulin secretion (insulinogenic index; 0.28 before treatment, 0.08 during octreotide LAR treatment) on 75 g oral glucose tolerance test (75gOGTT), despite decreases in GH and IGF-I levels during the course of octreotide LAR treatment. Postoperatively, both insulin sensitivity and early insulin secretion on 75gOGTT were improved (QUICKI 0.59, insulinogenic index 0.35). There are some reports that insulinogenic index is lower in most Japanese patients with type 2 diabetes mellitus and that early insulin secretions are significantly suppressed after administration of octreotide LAR. Although the influence of octreotide LAR on glucose metabolism varies among individuals, it is necessary to manage the deterioration of glucose tolerance during octreotide LAR treatment in acromegalic Japanese patients with decreased insulinogenic index.</description><identifier>ISSN: 0918-8959</identifier><identifier>EISSN: 1348-4540</identifier><identifier>DOI: 10.1507/endocrj.K06-143</identifier><identifier>PMID: 17339747</identifier><language>eng</language><publisher>Japan: The Japan Endocrine Society</publisher><subject>Acromegaly ; Acromegaly - complications ; Acromegaly - drug therapy ; Acromegaly - ethnology ; Acromegaly - etiology ; Asian Continental Ancestry Group ; Blood Glucose - metabolism ; Delayed-Action Preparations ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - diet therapy ; Diabetes Mellitus, Type 2 - physiopathology ; Diet, Diabetic ; Female ; Glucose Tolerance Test ; Humans ; Insulin - metabolism ; Insulin Secretion ; Insulinogenic index ; Middle Aged ; Octreotide ; Octreotide - adverse effects ; Octreotide - therapeutic use ; Pituitary Neoplasms - complications ; Pituitary Neoplasms - surgery ; QUICKI ; Treatment Outcome ; Type 2 diabetes mellitus</subject><ispartof>Endocrine Journal, 2007, Vol.54(2), pp.329-333</ispartof><rights>The Japan Endocrine Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-90cbfd210e91272fda04df61474cac2792273c6b7eac950654381efa1495b4773</citedby><cites>FETCH-LOGICAL-c486t-90cbfd210e91272fda04df61474cac2792273c6b7eac950654381efa1495b4773</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17339747$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KAHARA, Toshio</creatorcontrib><creatorcontrib>UENO, Keiko</creatorcontrib><creatorcontrib>TORITA, Muneyoshi</creatorcontrib><creatorcontrib>USUDA, Rika</creatorcontrib><creatorcontrib>ABE, Takumi</creatorcontrib><title>Deterioration of Glycemic Control during Octreotide LAR Treatment in an Acromegalic Japanese Patient with Type 2 Diabetes Mellitus</title><title>Endocrine Journal</title><addtitle>Endocr J</addtitle><description>We report a case showing deterioration of glycemic control during octreotide long-acting release (LAR) treatment in an acromegalic Japanese patient with type 2 diabetes mellitus. The patient did not show much improvement of insulin sensitivity (QUICKI; 0.33 before treatment, 0.35 during octreotide LAR treatment), and showed a significant reduction in early insulin secretion (insulinogenic index; 0.28 before treatment, 0.08 during octreotide LAR treatment) on 75 g oral glucose tolerance test (75gOGTT), despite decreases in GH and IGF-I levels during the course of octreotide LAR treatment. Postoperatively, both insulin sensitivity and early insulin secretion on 75gOGTT were improved (QUICKI 0.59, insulinogenic index 0.35). There are some reports that insulinogenic index is lower in most Japanese patients with type 2 diabetes mellitus and that early insulin secretions are significantly suppressed after administration of octreotide LAR. Although the influence of octreotide LAR on glucose metabolism varies among individuals, it is necessary to manage the deterioration of glucose tolerance during octreotide LAR treatment in acromegalic Japanese patients with decreased insulinogenic index.</description><subject>Acromegaly</subject><subject>Acromegaly - complications</subject><subject>Acromegaly - drug therapy</subject><subject>Acromegaly - ethnology</subject><subject>Acromegaly - etiology</subject><subject>Asian Continental Ancestry Group</subject><subject>Blood Glucose - metabolism</subject><subject>Delayed-Action Preparations</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - diet therapy</subject><subject>Diabetes Mellitus, Type 2 - physiopathology</subject><subject>Diet, Diabetic</subject><subject>Female</subject><subject>Glucose Tolerance Test</subject><subject>Humans</subject><subject>Insulin - metabolism</subject><subject>Insulin Secretion</subject><subject>Insulinogenic index</subject><subject>Middle Aged</subject><subject>Octreotide</subject><subject>Octreotide - adverse effects</subject><subject>Octreotide - therapeutic use</subject><subject>Pituitary Neoplasms - complications</subject><subject>Pituitary Neoplasms - surgery</subject><subject>QUICKI</subject><subject>Treatment Outcome</subject><subject>Type 2 diabetes mellitus</subject><issn>0918-8959</issn><issn>1348-4540</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtOAjEUhhujEUTX7kxfYKS3mU6XBO9iMAbXk07nDJTMhbQlhq1PbgkENz2Lfv9_2g-hW0ruaUrkGLqqN259_06yhAp-hoaUizwRqSDnaEgUzZNcpWqArrxfE8J5KvglGlDJuZJCDtHvAwRwtnc62L7DfY2fm52B1ho87bvg-gZXW2e7JZ6b4KAPtgI8m3zhhQMdWugCth3WHZ4Y17ew1E1MvumN7sAD_oyte-THhhVe7DaAGX6wuow7Pf6AprFh66_RRa0bDzfHOULfT4-L6Usymz-_TiezxIg8C4kipqwrRgkoyiSrK01EVWdUSGG0YVIxJrnJSgnaqJRk8ac5hVpTodJSSMlHaHzojS_13kFdbJxttdsVlBR7m8XRZhFtFtFmTNwdEptt2UL1zx_1RWB6ANY-6CWcAO2CNQ2cClNRsMPBmTrdmpV2EeF_jVCMSg</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>KAHARA, Toshio</creator><creator>UENO, Keiko</creator><creator>TORITA, Muneyoshi</creator><creator>USUDA, Rika</creator><creator>ABE, Takumi</creator><general>The Japan Endocrine Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2007</creationdate><title>Deterioration of Glycemic Control during Octreotide LAR Treatment in an Acromegalic Japanese Patient with Type 2 Diabetes Mellitus</title><author>KAHARA, Toshio ; UENO, Keiko ; TORITA, Muneyoshi ; USUDA, Rika ; ABE, Takumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-90cbfd210e91272fda04df61474cac2792273c6b7eac950654381efa1495b4773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Acromegaly</topic><topic>Acromegaly - complications</topic><topic>Acromegaly - drug therapy</topic><topic>Acromegaly - ethnology</topic><topic>Acromegaly - etiology</topic><topic>Asian Continental Ancestry Group</topic><topic>Blood Glucose - metabolism</topic><topic>Delayed-Action Preparations</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - diet therapy</topic><topic>Diabetes Mellitus, Type 2 - physiopathology</topic><topic>Diet, Diabetic</topic><topic>Female</topic><topic>Glucose Tolerance Test</topic><topic>Humans</topic><topic>Insulin - metabolism</topic><topic>Insulin Secretion</topic><topic>Insulinogenic index</topic><topic>Middle Aged</topic><topic>Octreotide</topic><topic>Octreotide - adverse effects</topic><topic>Octreotide - therapeutic use</topic><topic>Pituitary Neoplasms - complications</topic><topic>Pituitary Neoplasms - surgery</topic><topic>QUICKI</topic><topic>Treatment Outcome</topic><topic>Type 2 diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KAHARA, Toshio</creatorcontrib><creatorcontrib>UENO, Keiko</creatorcontrib><creatorcontrib>TORITA, Muneyoshi</creatorcontrib><creatorcontrib>USUDA, Rika</creatorcontrib><creatorcontrib>ABE, Takumi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Endocrine Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KAHARA, Toshio</au><au>UENO, Keiko</au><au>TORITA, Muneyoshi</au><au>USUDA, Rika</au><au>ABE, Takumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deterioration of Glycemic Control during Octreotide LAR Treatment in an Acromegalic Japanese Patient with Type 2 Diabetes Mellitus</atitle><jtitle>Endocrine Journal</jtitle><addtitle>Endocr J</addtitle><date>2007</date><risdate>2007</risdate><volume>54</volume><issue>2</issue><spage>329</spage><epage>333</epage><pages>329-333</pages><issn>0918-8959</issn><eissn>1348-4540</eissn><abstract>We report a case showing deterioration of glycemic control during octreotide long-acting release (LAR) treatment in an acromegalic Japanese patient with type 2 diabetes mellitus. The patient did not show much improvement of insulin sensitivity (QUICKI; 0.33 before treatment, 0.35 during octreotide LAR treatment), and showed a significant reduction in early insulin secretion (insulinogenic index; 0.28 before treatment, 0.08 during octreotide LAR treatment) on 75 g oral glucose tolerance test (75gOGTT), despite decreases in GH and IGF-I levels during the course of octreotide LAR treatment. Postoperatively, both insulin sensitivity and early insulin secretion on 75gOGTT were improved (QUICKI 0.59, insulinogenic index 0.35). There are some reports that insulinogenic index is lower in most Japanese patients with type 2 diabetes mellitus and that early insulin secretions are significantly suppressed after administration of octreotide LAR. Although the influence of octreotide LAR on glucose metabolism varies among individuals, it is necessary to manage the deterioration of glucose tolerance during octreotide LAR treatment in acromegalic Japanese patients with decreased insulinogenic index.</abstract><cop>Japan</cop><pub>The Japan Endocrine Society</pub><pmid>17339747</pmid><doi>10.1507/endocrj.K06-143</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-8959 |
| ispartof | Endocrine Journal, 2007, Vol.54(2), pp.329-333 |
| issn | 0918-8959 1348-4540 |
| language | eng |
| recordid | cdi_crossref_primary_10_1507_endocrj_K06_143 |
| source | MEDLINE; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; EZB-FREE-00999 freely available EZB journals |
| subjects | Acromegaly Acromegaly - complications Acromegaly - drug therapy Acromegaly - ethnology Acromegaly - etiology Asian Continental Ancestry Group Blood Glucose - metabolism Delayed-Action Preparations Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - diet therapy Diabetes Mellitus, Type 2 - physiopathology Diet, Diabetic Female Glucose Tolerance Test Humans Insulin - metabolism Insulin Secretion Insulinogenic index Middle Aged Octreotide Octreotide - adverse effects Octreotide - therapeutic use Pituitary Neoplasms - complications Pituitary Neoplasms - surgery QUICKI Treatment Outcome Type 2 diabetes mellitus |
| title | Deterioration of Glycemic Control during Octreotide LAR Treatment in an Acromegalic Japanese Patient with Type 2 Diabetes Mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T01%3A31%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deterioration%20of%20Glycemic%20Control%20during%20Octreotide%20LAR%20Treatment%20in%20an%20Acromegalic%20Japanese%20Patient%20with%20Type%202%20Diabetes%20Mellitus&rft.jtitle=Endocrine%20Journal&rft.au=KAHARA,%20Toshio&rft.date=2007&rft.volume=54&rft.issue=2&rft.spage=329&rft.epage=333&rft.pages=329-333&rft.issn=0918-8959&rft.eissn=1348-4540&rft_id=info:doi/10.1507/endocrj.K06-143&rft_dat=%3Cpubmed_cross%3E17339747%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17339747&rfr_iscdi=true |